Trade Longeveron Inc. - LGVN CFD
Add to favourite- Summary
- Historical Data
| Spread | 0.05 | ||||||||
|
Long position overnight fee
Long position overnight fee
Go to platform | -0.026179% | ||||||||
|
Short position overnight fee
Short position overnight fee
Go to platform | 0.003957% | ||||||||
| Overnight fee time | 21:00 (UTC) | ||||||||
| Min traded quantity | 1 | ||||||||
| Currency | USD | ||||||||
| Margin | 5% | ||||||||
| Stock exchange | United States of America | ||||||||
| Commission on trade | 0% |
| Prev. Close | 1.67 |
| Open | 1.67 |
| 1-Year Change | -44.7% |
| Day's Range | 1.64 - 1.67 |
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Change | Change (%) | Open | High | Low |
|---|---|---|---|---|---|---|
| May 6, 2024 | 1.67 | -0.05 | -2.91% | 1.72 | 1.72 | 1.65 |
| May 3, 2024 | 1.72 | -0.07 | -3.91% | 1.79 | 1.85 | 1.71 |
| May 2, 2024 | 1.77 | 0.02 | 1.14% | 1.75 | 2.02 | 1.67 |
| May 1, 2024 | 1.72 | 0.08 | 4.88% | 1.64 | 1.79 | 1.64 |
| Apr 30, 2024 | 1.68 | 0.07 | 4.35% | 1.61 | 1.76 | 1.61 |
| Apr 29, 2024 | 1.68 | 0.02 | 1.20% | 1.66 | 1.72 | 1.60 |
| Apr 26, 2024 | 1.69 | 0.04 | 2.42% | 1.65 | 1.77 | 1.59 |
| Apr 25, 2024 | 1.61 | -0.03 | -1.83% | 1.64 | 1.66 | 1.57 |
| Apr 24, 2024 | 1.70 | -0.06 | -3.41% | 1.76 | 1.78 | 1.65 |
| Apr 23, 2024 | 1.77 | -0.09 | -4.84% | 1.86 | 1.86 | 1.73 |
| Apr 22, 2024 | 1.84 | -0.10 | -5.15% | 1.94 | 2.03 | 1.79 |
| Apr 19, 2024 | 1.88 | -0.02 | -1.05% | 1.90 | 2.08 | 1.88 |
| Apr 18, 2024 | 1.95 | -0.10 | -4.88% | 2.05 | 2.24 | 1.89 |
| Apr 17, 2024 | 2.00 | -0.43 | -17.70% | 2.43 | 2.65 | 1.90 |
| Apr 16, 2024 | 3.49 | 0.53 | 17.91% | 2.96 | 4.23 | 2.59 |
| Apr 15, 2024 | 2.85 | 0.46 | 19.25% | 2.39 | 3.35 | 2.13 |
| Apr 12, 2024 | 1.64 | -0.40 | -19.61% | 2.04 | 2.06 | 1.57 |
| Apr 11, 2024 | 1.98 | -0.13 | -6.16% | 2.11 | 2.14 | 1.94 |
| Apr 10, 2024 | 2.19 | 0.23 | 11.73% | 1.96 | 2.27 | 1.96 |
| Apr 9, 2024 | 2.08 | 0.12 | 6.12% | 1.96 | 2.14 | 1.88 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 20
- 100
- 500
- 1000
- 10000
Longeveron Inc Company profile
Longeveron Inc. (LGVN) is a clinical-stage biotechnology company. Its lead drug component and cellular therapies address ageing and other life-threatening conditions. Founded in 2014, Longeveron is headquartered in Miami, US.
The biotech firm’s leading product Lomecel-B is derived from culture-expanded medicinal signalling cells (MSCs). The cells were sourced from young healthy adult donors’ - aged 18 to 45 - bone marrow to treat ageing-related diseases as they promote cell and tissue repair, organ maintenance and immune system function.
As of June 2022, the company is conducting Phase 2 clinical trials in hypoplastic left heart syndrome (HLHS) and Alzheimer’s disease. It has received orphan drug and rare paediatric disease designations from the US Food and Drug Administration (FDA).
Longeveron is also conducting Phase 1 and 2 clinical trials for ageing frailty, metabolic syndrome and acute respiratory distress syndrome due to Covid-19 or influenza.
Longeveron’s programmes have been awarded grant funding of more than $16.2m from various organisations, including the National Institute on Ageing (NIA), National Heart Lung and Blood Institute (NHLBI), the Alzheimer’s Association and the Maryland Stem Cell Research Fund (MSCRF).
Longeveron Inc. stock started trading on the NASDAQ stock exchange in February 2021 under the ticker symbol LGVN.
You can follow live LGVN stock price movements and price history and keep up with the latest LGVN share value at Capital.com
| Industry: | Biotechnology & Medical Research (NEC) |
1951 NW 7th Ave
Ste 520
MIAMI
FLORIDA 33136
US
News
We’re partnering with Newsquawk
Filter out the noise and focus on the news that matters.
08:32, 23 April 2024
US Earnings Season: Tesla, Alphabet, Meta Platforms and Microsoft
The first lot of Wall Street’s mega-cap tech companies report in the coming week. We preview what to expect from Tesla, Alphabet, Meta, and Microsoft’s quarterly results.
15:56, 22 April 2024
Gold price in 2024: geopolitical tensions and rate-cut expectations keep XAU/USD supported
Investors are keeping a close eye on gold as the conflict in the Middle East escalates with a possibility of a full-scale regional war in the area.
07:56, 17 April 2024
US Earnings Season : JP Morgan, Citigroup, Wells Fargo
The first major US banks report quarterly earnings on Friday, April 12th, 2024. We preview what to expect from JP Morgan, Citigroup, and Wells Fargo's quarterly numbers.
16:03, 11 April 2024
Reserve Bank of New Zealand Preview: Rates expected to remain on hold as inflation fight continues
The Reserve Bank of New Zealand (RBNZ) meets on Wednesday, April 10, 2024. We preview what to expect from the meeting and its possible impact on the NZD/USD.
09:22, 11 April 2024
US CPI Preview: US inflation expected to grind lower amid fears about sticky prices
US CPI data is released on Wednesday, 10 April. We preview what to expect from the data, how it could influence US Federal Reserve policy, and analyse the NASDAQ (US Tech 100).
15:11, 9 April 2024
How escalating geopolitical tensions are impacting oil markets
The bullish momentum in oil prices remains strong as escalating geopolitical tensions raise concerns about supply.
13:34, 4 April 2024People also watch
Still looking for a broker you can trust?
Join the 610,000+ traders worldwide that chose to trade with Capital.com